During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, GoBroad Healthcare Group, in collaboration with multiple partners, successfully hosted the “CHINA SUMMIT” in Chicago. The event attracted over 200 leading global oncology scholars and industry representatives onsite, with the online livestream reaching over 50,000 professionals. It served as a crucial bridge linking Chinese innovation with the global oncology community.

This year, the number of presentations delivered by Chinese experts at ASCO reached a record high. The “CHINA SUMMIT” featured outstanding researchers selected for oral presentations and abstracts at ASCO 2025, along with top global experts. The summit offered a powerful platform for sharing Chinese voices and promoting international collaboration in oncology research.

Opening Remarks and Institutional Commitment

The summit was co-chaired by Professors Jun Guo and Lin Shen from Peking University Cancer Hospital. Professor Jun Guo delivered the opening address, highlighting the significant progress and continuous innovation of Chinese pharmaceutical and biotech companies. He noted that China's role in global multi-center clinical trials is growing, and expressed his honor in sharing Chinese research achievements and practical experiences with international peers.

Mr. Xiaoyu Zheng, CEO of GoBroad Healthcare Group, welcomed all guests and emphasized that with the evolution of global clinical research paradigms, China is emerging as a key hub for early-stage drug development. As a pioneer in China’s research hospital ecosystem, GoBroad is committed to building an integrated clinical research system, empowering global pharmaceutical companies with high-quality early clinical data, and accelerating the journey of new drugs from lab to market. GoBroad’s scientific team also supports translational medicine, strategic development, and scientific evaluation of candidate drugs. Mr. Zheng expressed hopes for deeper global collaboration to push the boundaries of medical science for the benefit of patients worldwide.

Frontline Echoes: Recapturing ASCO Highlights

The summit brought together experts featured in ASCO 2025’s oral sessions and abstract presentations. Professors Xinan Sheng, Changsong Qi, Jing Pan, and Dongmei Ji from top Chinese institutions gave keynote speeches, recapturing ASCO 2025’s highlights. They shared groundbreaking research findings, China’s latest innovations in oncology, and insights into global trends in new drug development. These discussions collectively painted a visionary blueprint for the future of precision cancer medicine.

In-Depth Dialogues: Exploring China’s One-Stop Solutions

An interactive discussion session allowed for open global dialogue. Moderated by Mr. Xiaoyu Zheng, Professors Guo, Sheng, Qi, and Pan engaged in a deep discussion on “Entering China’s One-Stop Solutions.” They showcased how Chinese researchers are influencing global trial design and efficiency, and how collaboration with enterprises bridges the gap from lab to clinic. As researchers from GoBroad’s affiliated hospitals, the panelists detailed how GoBroad provides comprehensive local support for international projects, and expressed eagerness to deepen partnerships with overseas pharmaceutical companies to co-create a global innovation ecosystem in cancer research and treatment.

Youth Spotlight: USCACA ASCO Travel Award Ceremony

The summit featured a special “2025 USCACA ASCO Travel Award” ceremony. Dr. Panpan Zhang and Dr. Haoxin Peng from Peking University Cancer Hospital received the award, which honors young Chinese scholars who made outstanding contributions in translational or clinical cancer research at ASCO 2025.

Closing Remarks and Future Outlook

Professor Lin Shen delivered the closing remarks, summarizing the summit’s highlights and envisioning the future landscape of global oncology drug development. He encouraged more young Chinese researchers to become bridges for international exchange and congratulated everyone on the summit’s successful conclusion.

At ASCO 2025 and the “CHINA SUMMIT,” GoBroad Healthcare’s management and research teams showcased their capabilities and engaged in meaningful exchanges with global enterprises, research institutions, and industry experts. GoBroad’s one-stop IIT (Investigator-Initiated Trial) experience for overseas enterprises garnered wide attention. Moving forward, Gaobo Healthcare Group will continue working with global partners to advance high-quality oncology drug development. Through innovative technologies and its research hospital platform, Gaobo aims to enhance clinical trial efficiency and help bring more breakthrough therapies to patients around the world.